Q-omics provides the consensus-scored TTC1 profile across patient tissues and cancer cell-line models. TTC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TTC1 protein abundance shows 29,626 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, and UCEC as cancer lineages where TTC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC1 survival associations across molecular data types. TTC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC1 RNA expression–survival associations across cancer types. High TTC1 expression shows unfavorable associations in HNSC, LIHC, UVM, STAD and KIRP, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC1 RNA expression.
This table summarizes TTC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, LIHC, ESCA, BRCA and CHOL. The KIRC box plot shows higher TTC1 RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with TTC1 in patient tissues and cancer cell lines. In patient samples, TTC1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
